Group 1 - The core viewpoint of the news is that Beijing Puxi Pharmaceutical Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to become a leader in targeted therapy for immune inflammation [1] - The company was established in 2016 and focuses on innovative original design and precise local delivery in the treatment of chronic inflammatory diseases [1] - Puxi Pharmaceutical aims to provide innovative solutions that balance efficacy, safety, and long-term patient satisfaction [1] Group 2 - Puxi Pharmaceutical has developed its core product PG-011 (Pumeixinine), which comes in two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis [3] - The company also has a diversified pipeline of candidate products, including PG-033 tablets for pruritus, PG-018 tablets for autoimmune kidney disease, and PG-040 eye drops for glaucoma [3]

Group 1 - The core viewpoint of the article is that Beijing Puxi Pharmaceutical Technology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, aiming to become a leader in targeted therapy for immune inflammation [1] - The company was established in 2016 and focuses on innovative design and precise local delivery in the treatment of chronic inflammatory diseases, providing effective, safe, and long-term patient satisfaction solutions [1] Group 2 - Puxi Pharmaceutical has developed its core product PG-011 (Pumeixinine), which comes in two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis [3] - The company also has a diversified pipeline of candidate products, including PG-033 tablets for pruritus, PG-018 tablets for autoimmune kidney disease, and PG-040 eye drops for glaucoma [3]